It is well-known immune checkpoint inhibitors (ICIs) which block coinhibitory molecules such as CTLA-4, programmed cell death protein-1 (PD-1), and the related programmed death-ligand 1 (PD-L1) have changed the treatment scenario of advanced NSCLC first-line setting as breakthroughs. Here, CD274 is linked to non-small cell lung carcinoma.